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Abstract Objective: Compare
duration of mechanical ventilation
(MV), weaning time, ICU-LOS (ICU-
LOS), efficacy and safety of remif-
entanil-based regimen with
conventional sedation and analgesia.
Design: Centre randomised, open-
label, crossover, ‘real-life’ study.
Setting: 15 Dutch hospitals.
Patients: Adult medical and post-
surgical ICU patients with anticipated
short-term (2–3 days) MV. Interven-
tions: Patient cohorts were
randomised to remifentanil-based
regimen (n = 96) with propofol as
required, for a maximum of 10 days,
or to conventional regimens
(n = 109) of propofol, midazolam or
lorazepam combined with fentanyl or
morphine. Measurements and main
results: Outcomes were weaning
time, duration of MV, ICU-LOS,
sedation- and analgesia levels, in-
tensivist/ICU nurse satisfaction,
adverse events, mean arterial
pressure, heart rate. Median duration
of ventilation (MV) was 5.1 days
with conventional treatment versus
3.9 days with remifentanil (NS). The
remifentanil-based regimen reduced
median weaning time by 18.9 h
(P = 0.0001). Median ICU-LOS was
7.9 days versus 5.9 days, respectively
(NS). However, the treatment effects
on duration of MV and ICU stay were
time-dependent: patients were almost
twice as likely to be extubated
(P = 0.018) and discharged from the
ICU (P = 0.05) on day 1–3. Propofol
doses were reduced by 20%
(P = 0.05). Remifentanil also
improved sedation-agitation scores
(P \ 0.0001) and intensivist/ICU
nurse satisfaction (P \ 0.0001). All
other outcomes were comparable.
Conclusions: In patients with an
expected short-term duration of MV,
remifentanil significantly improves
sedation and agitation levels and
reduces weaning time. This contrib-
utes to a shorter duration of MV and
ICU-LOS.
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Introduction
The vast majority of patients admitted to the intensive
care unit (ICU) receive both analgesic (opioid) and sed-
ative agents to control pain, relieve agitation and anxiety,
aid compliance with mechanical ventilation (MV), and
hence overall, to help maintain comfort [1]. When
administered over several days, the pharmacodynamic
effects of conventional opioids such as fentanyl and
morphine become unpredictable and are often prolonged
as a result of re-distribution and accumulation [2]. This
may increase the risk of suppressed respiratory drive and
potentially delay weaning and extend the duration of MV.
Important levers to reduce the duration of MV are its
well-known risks, including complications directly related
to the process of intubation and MV such as injury to the
trachea and to lung tissue, and complications caused by
loss of airway defence mechanisms such as nosocomial
pneumonia [3–5]. Reduction of the duration of MV may
also yield savings in terms of reduced ICU and hospital
length of stay and reduced costs [6]. It has further been
suggested that from a patient’s point of view, perhaps the
most troubling aspects are the tube-associated discomfort
and the compromised ability to eat and to communicate,
contributing to feelings of powerlessness, isolation, and
anxiety [3, 7].
Remifentanil is a selective l-opioid receptor agonist
with a potency similar to fentanyl [8]. It has a rapid onset
of action (blood-brain equilibration half-time & 1 min)
and, unlike existing opioids, is metabolized in an organ-
independent fashion by non-specific esterases in the blood
and tissues into an inactive metabolite [9]. This results in
a short context sensitive half-time of approximately
4 min, without accumulation after prolonged infusion
[10]. The rapid esterase metabolism provides a predict-
able pharmacokinetic profile, which is independent of the
dose and duration of infusion and of the patient’s renal or
hepatic function [10, 11]. Remifentanil’s organ-indepen-
dent metabolism and predictable pharmacokinetic profile
allow that in a remifentanil-based analgesia and sedation
regimen, the opioid is used as the main drug to provide
patient comfort, while the use of the sedative agent is kept
to a minimum.
Predicting the duration of MV and ICU stay can be
difficult and the use of long-acting sedatives/analgesics in
the early phase of ICU admission can prolong the duration
of MV when a patient recovers more quickly than
expected [12]. In such unpredictable circumstances, a
short-acting agent may improve the speed of weaning,
shorten the duration of MV, and advance ICU discharge.
Therefore, we conducted a centre randomised, open-label,
crossover study in a ‘real-life’ setting to compare the
duration of MV, weaning time, ICU-LOS, efficacy, and
safety of a remifentanil-based analgesia and sedation
regimen to conventional sedation and analgesia regimens
in a mixed group of medical and post-surgical ICU
patients with anticipated short-term (2–3 days) MV fol-
lowing the start of the study medication. Preliminary
results of this study were published as an abstract at the
2006 ESICM meeting [13].
Materials and methods
A description of the materials and methods of this study,
including a graphical presentation of the study phases and
assessments, is available as electronic supplementary
material.
Results
Patients
Of 205 patients recruited at 15 medical centres (one of the
planned centres did not participate in the study), 109 were
randomised to receive the conventional sedation and
analgesia regimen and 96 to receive the remifentanil-
based analgesia and sedation regimen. Patient demo-
graphics and baseline characteristics of the groups were
well-balanced (Table 1). The study medication usage and
doses are summarized in Table 2. During the 10-day
treatment period, 9 (8%) patients in the conventional arm
versus 25 (26%) in the remifentanil arm were withdrawn
for reasons other than decease (P = 0.001). These rea-
sons were: practical problems not related to sedation or
analgesia (1 vs. 10%), lack of efficacy (2 vs. 5%), trans-
ferred outside the ICU (3 vs. 2%), change in status of
exclusion criteria (3 vs. 1%), adverse events (0 vs. 2%),
withdrawal of consent (0 vs. 2%), subjects detriment to
continue in the study (0 vs. 1%) or other (0 vs. 3%). In
addition, 15 patients in the conventional treatment group
new switched to another analgesic or hypnotic agent
during the treatment period without being withdrawn. In
both study arms, half of the withdrawals occurred within
the first 2 days of treatment. Eleven (10%) patients in the
conventional arm vs. 9 (9%) in the remifentanil arm died
on a study treatment day (P = 1.0), and 23 (21%) patients
in the conventional arm vs. 8 (8%) in the remifentanil arm
were still ventilated by the end of day 10 (P = 0.019)
(Fig. 1).
Primary end point
The median duration of MV over the 10-day treatment
period was 5.1 days (95% confidence interval: 3.5, 6.7) in
the conventional arm vs. 3.9 days (95% confidence
interval: 2.6, 5.2) in the remifentanil arm (Fig. 2). As the
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treatment effect on the duration of MV was time
dependent (P = 0.002), significance testing for the whole
study treatment period was not valid with the Cox’s
proportional-hazards model. Therefore, the treatment
period was split into 2 periods: day 1–3 and day 4–10.
Patients in the remifentanil arm were 1.86 times more
likely to be extubated on day 1–3 of treatment than
patients in the conventional arm (95% confidence
interval: 1.11, 3.11; P = 0.018). Based on this rate ratio
of 1.86, the expected percentage of extubated patients on
day 1 will increase from 8% with the conventional
regimen to 14% (= 1 - e1.86 9 ln(1 - 0.08)) with the
remifentanil-based regimen, on day 2 from 23 to 39%,
and on day 3 from 34 to 54%. The percentages of ex-
tubated patients with the conventional regimen were
taken from the Kaplan–Meier curve. No difference was
observed for day 4–10 (rate ratio, 0.98; 95% confidence
interval: 0.47, 2.04; P = 0.951).
Table 1 Patient
demographics and baseline
characteristics
Conventional sedation
and analgesia regimen
Remifentanil-based
analgesia and sedation
regimen
P value
Number of patients 109 96
Medical patients, n (%) 69 (63%) 54 (56%) 0.32
Post-surgical patients, n (%) 40 (37%) 42 (44%)
Emergency 18 (45%) 23 (55%) 0.51
Elective 22 (55%) 19 (45%)
Dx medical patients, n (%)
Cardiovascular 7 (10%) 7 (13%) 0.52
Respiratory 46 (67%) 36 (67%)
Gastrointestinal 2 (3%) 2 (4%)
Sepsis 11 (16%) 4 (7%)
Other 3 (4%) 5 (9%)
Dx surgical patients, n (%)
Cardiovascular 11 (27.5%) 15 (36%) 0.90
Respiratory 2 (5%) 2 (5%)
Gastrointestinal 23 (57.5%) 22 (52%)
Other 4 (10%) 3 (7%)
Age, mean yearsa 64 ± 14 66 ± 13 0.53
Gender, % male 63% 61% 0.89
Weight, mean kga 80 ± 14 78 ± 16 0.30
SAPS II, mean scorea 46 ± 14 44 ± 16 0.22
MAP, mean mm Hga 75 ± 15 80 ± 19 0.0028
HR, mean bpma 96 ± 23 91 ± 22 0.80
SAS, mean scorea 2.2 ± 1.3 2.3 ± 1.5 0.87
PI, mean scorea 1.3 ± 0.6 1.4 ± 1.0 0.91
Dx diagnosis; HR heart rate, MAP mean arterial pressure, PI pain intensity, SAPS II simplified acute
physiology scores, SAS sedation–agitation scale
a Data are presented as mean ± standard deviation
Differences in proportions between the groups were tested with the Chi-square test. Mean differences
in the continuous variables were tested with the t-test except SAS and PI scores which were tested with
the Mann–Whitney test
Table 2 Exposure to study medication
Proportion of patients using
the agent (%)a
Bolus dose Infusion dose
Median doseb Frequency per 24 h
(in n patients used)
Median dosea
(in n patients used)
Conventional sedation and analgesia regimen
Morphine 58 0.05 mg/kg 0.64 (10) 0.03 mg/kg/h (63)
Fentanyl 38 0.92 lg/kg 0.63 (18) 1.05 lg/kg/h (38)
Midazolam 81 0.06 mg/kg 0.64 (39) 0.07 mg/kg/h (84)
Propofol 46 0.56 mg/kg 0.61 (19) 1.43 mg/kg/h (46)
Lorazepam 7 0.03 mg/kg 0.57 (6) 0.02 mg/kg/h (6)
Remifentanil-based analgesia and sedation regimen
Remifentanil 100 – – 9.0 lg/kg/h (96)
Propofol 65 0.48 mg/kg 1.64 (50) 1.15 mg/kg/h (61)
a In the conventional arm 1% of the subjects used piritramide and 3% used sufentanil (protocol violations)
b Median time-weighted average dose per patient when used
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Secondary end points
The median weaning time was 24.8 h (95% confidence
interval: 21.4, 28.1) in the conventional arm vs. 5.9 h
(95% confidence interval: 0.8, 11.0) in the remifentanil
arm (P = 0.0001) (Fig. 3). The median ICU-LOS was
7.9 days (95% confidence interval: 5.1, 10.6) vs. 5.9 days
(95% confidence interval: 4.9, 7.0), respectively. Patients
on remifentanil arm were 1.89 times more likely to be
discharged from the ICU on day 1–3 of treatment than
patients on conventional treatment (95% confidence
interval: 1.00, 3.59; P = 0.05). The 83rd percentile value
for ICU-LOS was 3.0 days for the conventional arm
versus 1.8 days for the remifentanil arm. No difference
was observed for day 4–28 (rate ratio, 1.14; 95% confi-
dence interval: 0.73, 1.76; P = 0.570).
The median time-weighted average infusion rates and
bolus doses of the study drugs are reported in Table 2.
The infusion rate of propofol was 1.43 mg/kg/h for those
patients receiving propofol in the conventional treatment
arm versus 1.15 mg/kg/h for those in the remifentanil-
based treatment group (P = 0.05).
In the remifentanil group, a total of 28 subjects
received the following 41 episodes of post extubation
medications: paracetamol 10, NSAID 1, piritramide 3,
morphine 11, bupivacaine 6, fentanyl 2, sufentanil 4,
clonidine 1, midazolam 1, lorazepam 1 and oxazepam 1.
Patients in the remifentanil arm had consistently and
significantly better SAS scores over the 10-day treatment
period than patients in the conventional arm (mean
weighted average ± SD, 3.3 ± 0.9 vs. 2.5 ± 1.0;
P \ 0.0001). PI scores did not significantly differ between
the study arms (mean weighted average ± SD, 1.3 ± 0.5
vs. 1.2 ± 0.4; P = 0.120). The proportion of ‘excellent’
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Fig. 2 Kaplan–Meier plot of the duration of mechanical ventilation
(intention-to-treat population). Dotted curve conventional sedation
and analgesia regimen, continuous curve Remifentanil-based
analgesia and sedation regimen. P value (1-3 days): 0.018, P
value (4-10 days): 0.951
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Fig. 3 Kaplan–Meier plot of the weaning time (intention-to-treat
population). Dotted curve conventional sedation and analgesia
regimen. Continuous curve remifentanil-based analgesia and seda-
tion regimen. P value: 0.0001
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Fig. 1 Percentage of patients extubated, withdrawn, deceased, or
still intubated by the end of day 10. a Conventional sedation and
analgesia regimen (n = 109). b Remifentanil-based analgesia and
sedation regimen (n = 96). Unshaded areas extubated, stripped
areas withdrawn, shaded areas deceased, dotted areas still
intubated
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and ‘very good’ intensivist and nurse satisfaction scores
for patient analgesia and extubation was significantly
higher with the remifentanil-based regimen compared to
the conventional regimen (P \ 0.0001) (Table 3).
Safety
MAP and HR values were comparable between the study
regimens over the 10-day treatment period. Mean time-
weighted MAP was 79.4 mm Hg ± 12.1 for remifentanil
and 78.3 mm Hg ± 10.3 for conventional treatment
(P = 0.517). Mean time-weighted HR was 88.0 bpm ±
16.4 and 92.0 bpm ± 15.0, respectively (P = 0.070).
Twelve non-serious adverse events were observed in 6
patients (6%) in the conventional arm and 6 non-serious
adverse events in 6 patients (6%) in the remifentanil arm
(P = 0.481). Three of these events (hypotension, neuritis
motor, and withdrawal syndrome) were considered related to
remifentanil treatment. The patient with hypotension was
withdrawn from the study medication. Eleven serious
adverse events were observed in 10 patients (9%) in the
conventional arm and 13 serious adverse events in 10
patients (10%) in the remifentanil arm (P = 0.612). None of
these events were considered related to the study medication.
Discussion
This centre randomised, open-label, crossover study in a
broad spectrum of mechanically ventilated patients
showed that patients receiving a remifentanil-based
analgesia and sedation regimen required a significantly
shorter weaning time. As a result, they were almost twice
as likely to be extubated and discharged from the ICU
within the first 3 days of treatment compared to patients
receiving a conventional sedation and analgesia regimen.
We chose an open-label design to allow comparison
of techniques rather than treatments. A conventional
sedation and analgesia regimen differs from a remifen-
tanil-based analgesia and sedation regimen in terms of
momentum and action of intervention. Because switching
regularly between the regimens as in patient-randomised
designs is difficult, a centre randomised, cross-over
design was chosen. When all sites completed their first
cohort of patients, they started enrolling an equal number
of patients for the next cohort. This design precludes a
possible time-effect and between-centre variability.
Remifentanil was administered for a maximum of
10 days, as safety and efficacy data on remifentanil use
longer than 10 days were not available at the time of the
start of patient enrolment. To our knowledge, only 3
previous studies have reported on prolonged infusion of
remifentanil in an ICU setting [14–16].
The treatment effect for duration of MV and for ICU-
LOS was time-dependent. The cut-off point for time-
dependency was set at 3 days, because we aimed at
including patients who were expected to require short-
term (2–3 days) MV. Moreover, the safety and efficacy
for longer treatment of ICU patients with remifentanil had
not been fully established yet. Hence, current prescribing
information does not recommend remifentanil in ICU
patients for more than 3 days.
Whilst the patients in the remifentanil-based treatment
group were almost twice as likely to be extubated within
the first 3 days of treatment, no significant difference in
the duration of MV was observed for the entire 10-day
treatment period. Sixty percent of patients were still
intubated after day 3 despite the inclusion criterion of an
anticipated 2–3 days of MV. This caused the study to be
underpowered. To date, three studies have shown a sig-
nificant reduction in the duration of MV with remifentanil
compared to conventional regimens [14, 17, 18], whereas
1 other did not [19]. For the day 4–10 treatment period, no
significant difference was found whilst one would expect
patients undergoing longer sedation to benefit even more
due to the favourable pharmacokinetics of remifentanil.
This can be explained by the high number of patients who
Table 3 Intensivist and intensive care nurse satisfaction with analgesia, sedation, extubation, and ease of study drug usage (in n patients
assessed)
C R C R C R C R
Analgesia Sedation Extubation Usage comfort
Intensivist satisfaction
Poor 0% (0) 3.1% (3) 0.9% (1) 8.3% (8) 1.6% (1) 0% (0) 0% (0) 2.1% (2)
Good/fair 89% (97) 52.1% (50) 90.8% (99) 62.5% (60) 90.5% (57) 55.5% (30) 88.1% (96) 67.7% (65)
Excellent/very good 11% (12) 44.8% (43) 8.3% (9) 29.2% (28) 7.9% (5) 44.5% (24) 11.9% (13) 30.2% (29)
P value \0.0001 0.26 \0.0001 0.31
Intensive care nurse satisfaction
Poor 0% (0) 1% (1) 0.9% (1) 6.3% (6) 1.6% (1) 1.9% (1) 0.9% (1) 2.1% (2)
Good/fair 72.5% (79) 56.3% (54) 77.1% (84) 66.6% (64) 87.5% (56) 62.9% (34) 80.7% (88) 71.8% (69)
Excellent/very good 27.5% (30) 42.7% (41) 22% (24) 27.1% (26) 10.9% (7) 35.2% (19) 18.4% (20) 26.1% (25)
P value 0.030 0.25 0.007 0.80
C conventional sedation and analgesia regimen, R remifentanil-based analgesia and sedation regimen
Mann–Whitney test
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were still intubated at day 10 (21% of the patients in the
conventional regimen patients versus 8% of the patients in
the remifentanil-based regimen).
The shorter median weaning time in the remifentanil
arm is probably directly related to remifentanil’s phar-
macokinetic profile. Three active comparator studies have
also shown significant reductions in weaning time with
remifentanil [14, 15, 18], whereas 1 other has not [20].
Patients in the remifentanil arm had a 1.89 higher
chance of ICU discharge during the first 3 days of treat-
ment. Previous studies showed mixed results: two studies
found a significant reduction in ICU-LOS with remifen-
tanil vs. conventional regimens [17, 18], whereas four
others did not [14, 15, 19, 20]. Discharge from ICU
depends not only on treatment-related factors, but also on
managerial factors, such as the availability of beds and
staff, and time of the day.
The median time-weighted average infusion rate of
remifentanil infusion was 9.0 lg/kg/h, which is well
within the rates reported previously in ICU patients
[14, 18, 20] and the Summary of Product Characteristics
of remifentanil (dose range, 0.4–45 lg/kg/h). The median
time-weighted average infusion rate of propofol was 20%
lower in the remifentanil arm compared to the conven-
tional arm. This affirms remifentanil’s sedative-sparing
effect and is in keeping with previous clinical trials in
ICU patients [14, 18, 20, 21]. The consistently better SAS
scores in the remifentanil arm indicate that this agent is
easier to titrate to optimal response than the conventional
agents used in our study.
Study strengths and limitations
Our study was not blinded and is thus open to all usual
criticism that applies to such studies. However, the results
reflect the consequences of treating a broad population of
medical and post-surgical patients in a ‘real life’ setting and
by using the routine logistics of the investigational sites.
More patients in the conventional arm were still venti-
lated by the end of day 10. This finding is difficult to
interpret, because the withdrawal rate in the remifentanil
arm was higher than in the conventional arm and patients
who were withdrawn were not followed up for MV details.
The higher withdrawal rate with remifentanil may be
explained by unfamiliarity with remifentanil and the fact
that the conventional arm had more analgesia and sedation
treatment options: any combination of fentanyl or morphine
with either propofol, midazolam, or lorazepam was allowed.
In fact, 15 patients in the conventional arm were switched to
another hypnotic agent during the study treatment period.
So, in both study groups a comparable number of patients
changed their initial analgesia and sedation regimen.
The guidelines of the Dutch Society of Intensive Care
specify the bolus and maintenance dose of drugs for
analgesia and sedation. They do not include specific
instructions for dose adjustments of analgesia and sedation
like a daily interruption or a weaning protocol. In accor-
dance with the Dutch guidelines, our study protocol did
not include specific instructions for adjustments or wean-
ing in both study arms. However, as our study
demonstrated benefit of the remifentanil-based regimen
over the first 3 days of treatment, the impact of daily
interruptions in this short period may have been limited. In
addition, the median duration of MV in the conventional
arm (5.1 days) was comparable to that seen in the inter-
vention arm with daily interruption in the study by Kress
et al. (4.9 days) [22]. Whether the effect of a sedation
protocol on ventilation time and ICU stay is more
important than the choice of the analgesic- and sedative
agent is questionable, but a recent study shows that
improvement in weaning time can still be achieved with
remifentanil on top of a daily interruption protocol [23].
Study implications
Our results have several medical and managerial impli-
cations. A shorter duration of MV has the potential to
reduce complications associated with prolonged intubation
and ventilation and to limit patient discomfort [4, 5]. Once
familiar with remifentanil, it is easy to titrate to response
with limited use of sedative agents. A reduction in ICU-
LOS increases ICU capacity in terms of beds and staff,
reduces costs, and allows more flexible ICU bed man-
agement. Our study affirms that prediction of the duration
of MV is difficult. Therefore, we propose to start patients
on a remifentanil-based regimen whenever short-term MV
is anticipated and to evaluate after 2–3 days of treatment.
If at that point longer-term MV is anticipated, for example
due to (increased risk of) complications, patients may be
switched to conventional analgesics and sedatives.
Conclusions
We conclude that in patients with anticipated short-term
duration of MV, a remifentanil-propofol analgo-sedation
regimen provides better control of sedation and agitation
and reduces weaning time compared to conventional
regimens. In addition, patients on a remifentanil-propofol
based regimen are almost twice as likely to be extubated
and discharged from the ICU within the first 3 days of
treatment than patients on conventional regimens. Both
regimens are equally well tolerated.
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